Investigation of the Adverse Events and Efficacy of Docetaxel+Cisplatin+5-Fluorouracil in Patients with Head and Neck Squamous Cell Carcinoma

DOI Web Site Web Site 15 References
  • Tasaki Akihisa
    Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical and Dental University
  • Sugimoto Taro
    Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical and Dental University Department of Otorhinolaryngology-Head and Neck Tumor Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
  • Sumi Takuro
    Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical and Dental University Sumi ENT Clinic
  • Kiyokawa Yusuke
    Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical and Dental University
  • Nomura Fuminori
    Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical and Dental University
  • Ariizumi Youske
    Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical and Dental University
  • Kishimoto Seiji
    Department of Head and Neck Surgery, Kameda General Hospital
  • Asakage Takahiro
    Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical and Dental University

Bibliographic Information

Other Title
  • 頭頸部癌に対する Docetaxel, Cisplatin, 5-FU (TPF療法) 同時併用化学放射線療法における有効性および有害事象の検討
  • トウケイブガン ニ タイスル Docetaxel, Cisplatin, 5-FU(TPF リョウホウ)ドウジ ヘイヨウ カガク ホウシャセン リョウホウ ニ オケル ユウコウセイ オヨビ ユウガイ ジショウ ノ ケントウ

Search this article

Abstract

<p>　The objective of this study was to evaluate the adverse events and efficacy of treatment with the combination regimen of docetaxel, cisplatin, and 5-fluorouracil (TPF) in patients with head and neck cancer.</p><p></p><p>　We retrospectively analyzed the data of 82 patients with locally advanced head and neck cancer who underwent treatment with TPF between January 2012 and December 2014. We investigated the early and late toxicities and efficacy of the treatment. The 3-year overall survival rate was 70.7%, the locoregional control rate was 64%, and the disease-free survival rate was 62.8%. Grade≧3 neutropenia was observed in 82.9% of the patients (n=68) and febrile neutropenia (FN) was observed in 51.2% of the patients (n=42). The late toxicity rate may be lower than that reported previously.</p><p></p><p>　TPF-CCRT treatment compared rather favorably with CDDP-CCRT treatment. The incidence of FN was higher than 20%, and the prophylactic use of granulocyte-colony stimulating factor (G-CSF) was necessary. Serious adverse events are commonly observed in patients undergoing treatment with TPF; hence, this treatment should be provided in experience-rich facilities.</p>

Journal

References(15)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top